Like Causes?

Install the App
TRY NOW

senate Bill S. 164

Advancing Education on Biosimilars Act of 2021

Bill Details

Official information provided by the Congressional Research Service. Learn more or make a suggestion.
The Congressional Research Service writes summaries for most legislation. These summaries are listed here. Causes will update some legislation with a revised summary, title or other key elements.

Suggest an update to this bill using our form.

Title

Advancing Education on Biosimilars Act of 2021

Official Title

Advancing Education on Biosimilars Act of 2021

Summary

Advancing Education on Biosimilars Act of 2021 This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.) The FDA may also maintain and operate a website to provide educational materials about biological products.

bill Progress


  • Not enacted
    The President has not signed this bill
  • The house has not voted
  • The senate has not voted
    IntroducedFebruary 2nd, 2021

    There are currently no opinions on this bill, be the first to add one!